Celularity
Clinical-stage biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta.
Launch date
Employees
Market cap
€56.0m
Enterprise valuation
€115m (Public information from Sep 2024)
Share price
$2.56 CELU
Florham Park New Jersey (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 14.3m | 21.3m | 18.0m | 22.8m | 19.6m |
| % growth | - | 49 % | (16 %) | 27 % | (14 %) |
| EBITDA | (65.5m) | (96.9m) | (141m) | (74.3m) | - |
| % EBITDA margin | (458 %) | (454 %) | (785 %) | (326 %) | - |
| Profit | (208m) | (100m) | 14.2m | (196m) | - |
| % profit margin | (1458 %) | (469 %) | 79 % | (862 %) | - |
| EV / revenue | - | 29.3x | 13.3x | 4.9x | - |
| EV / EBITDA | - | -6.5x | -1.7x | -1.5x | - |
| R&D budget | 52.7m | 88.4m | 78.4m | 30.5m | - |
| R&D % of revenue | 369 % | 414 % | 436 % | 134 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $40.0m | Early VC | |
$250m | Early VC | ||
| N/A | N/A | IPO | |
$300m Valuation: $1.3b 87.5x EV/LTM Revenues -19.1x EV/LTM EBITDA | SPAC IPO | ||
$372m Valuation: $1.3b 87.5x EV/LTM Revenues -19.1x EV/LTM EBITDA | SPAC Private Placement | ||
$80.0m | Post IPO Equity | ||
* | N/A | $30.0m | Private Placement VC |
* | $6.0m | Private Placement VC | |
* | $15.0m | Post IPO Debt | |
| Total Funding | €635m | ||
